<DOC>
	<DOCNO>NCT00235924</DOCNO>
	<brief_summary>The main objective study determine effect endometrium breast 70 mg daily dose isoflavones .</brief_summary>
	<brief_title>Study Assessing Effects Endometrium Breast Isoflavone Post Menopausal Women</brief_title>
	<detailed_description>This international multicentre open study , assess innocuity breast endometrium 70 mg daily dose isoflavones standardize extract ( Phytosoya ) . This study follow European guideline : one-year treatment duration , biopsy mammography perform begin end trial , recruitment enough subject order 300 patient evaluable biopsy one year treatment . After 3 week screen phase , patient take Phytosoya 52 week . At end first year treatment , endometrial biopsy , endovaginal ultrasonography , mammography , breast ultrasound , clinical examination biological assessment perform . In addition , propose patient continue treatment 2 additional year . At end third year , examination perform .</detailed_description>
	<criteria>Not hysterectomised woman Post menopausal ( least 2 year ) FSH superior 30 UI/l oestradiol inferior 35 ng/ml Presenting hot flush ( incapacitate ) climacteric symptom History endometrial hyperplasia Known hormonodependent malignant tumours BMI superior 30 Kg/m2 Uncontrolled arterial hypertension Known renal liver insufficiency Recent evolutive thromboembolic disease Unexplained bleeding , endometrial polyp , submucous myoma , active endometriosis , ovarian cyst superior 30 mm Local hormonal treatment , raloxifene , tibolone within 3 month V1 study HRT DHEA within 3 month V2 study isoflavones within 2 month V2 study clonidine , betaalanine , veralipride within 1 month V1 study .</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2005</verification_date>
	<keyword>menopause</keyword>
	<keyword>isoflavone</keyword>
	<keyword>endometrial safety</keyword>
	<keyword>breast innocuity assessment</keyword>
	<keyword>hot flush</keyword>
</DOC>